Genetic Technologies Share Price and Company Fundamentals
Last traded: 10/16/2024
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Maroochydore, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
0.23
Market cap
$5.67M
Enterprise value
$5.16M
Company profile
| Industry / Sector | Diagnostics & Research / Healthcare |
|---|---|
| Full time employees | 55 |
| Website | https://genetype.com |
| Mailing address | T1 404 Kon-Tiki Business Centre 55 Plaza Parade Maroochydore QLD 4558 Australia |
| Phone / Fax | 61 3 0087 6693 / |
Dividends
More: Genetic Technologies Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Genetic Technologies paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GTG dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Genetic Technologies.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Kevin Camilleri | Chief Executive Officer of EasyDNA | 47 | |
| Mr. Michael Walker | Executive Chairman & MD | ||
| Mr. Jules Grove | Chief Financial Officer | ||
| Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA | Consultant | 62 | |
| Ms. Priyamvada Sanjay Rasal | Company Secretary | ||
| Dr. Erika Spaeth Ph.D. | Director of Clinical & Scientific Affairs |
Profitability and management effectiveness
Profit margin
-105.58%
Operating margin
-337.15%
Return on assets
-119.82%
Return on equity
-979.86%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Genetic Technologies is 5.67M and its enterprise value is 5.16M. The enterprise value to revenue ratio of GTG is 0.56. The enterprise value to EBITDA ratio of GTG is -0.54.
The GTG's stocks Beta value is 0.23 making it 77% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Genetic Technologies (GTG)
Genetic Technologies (ASX:GTG) Frequently Asked Questions
1. What is Genetic Technologies's Stock Symbol?
Genetic Technologies trades on ASX under the ticker symbol "GTG".
2. What is Genetic Technologies's stock price today?
One share of GTG stock can currently be purchased for approximately $0.039.
3. How can I contact Genetic Technologies?
Genetic Technologies's mailing address is T1 404 Kon-Tiki Business Centre 55 Plaza Parade Maroochydore QLD 4558 Australia. The company can be reached via phone at 61 3 0087 6693.
4. What is Genetic Technologies's official website?
The official website of Genetic Technologies is https://genetype.com.